Apis Capital Advisors LLC Takes $4.35 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Apis Capital Advisors LLC has acquired a new position in ANI Pharmaceuticals, purchasing 65,000 shares valued at about $4.35 million, making it the firm's 15th largest holding.
• ANI Pharmaceuticals reported earnings per share (EPS) of $1.80 for the last quarter, exceeding analyst expectations, with revenue increasing by 53.2% compared to the same quarter last year.
• Insiders have sold a total of 405,538 shares over the last 90 days, representing a significant decrease in their ownership stakes.

Apis Capital Advisors LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the specialty pharmaceutical company's stock, valued at approximately $4,352,000. ANI Pharmaceuticals comprises 2.1% of Apis Capital Advisors LLC's portfolio, making the stock its 15th biggest position. Apis Capital Advisors LLC owned 0.30% of ANI Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Hohimer Wealth Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after acquiring an additional 247 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after acquiring an additional 364 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock worth $630,000 after acquiring an additional 675 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after acquiring an additional 881 shares during the last quarter. Finally, National Bank of Canada FI purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth $79,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Stock Up 1.1%

ANI Pharmaceuticals stock traded up $1.08 during mid-day trading on Thursday, reaching $96.00. The stock had a trading volume of 398,510 shares, compared to its average volume of 375,436. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -124.67 and a beta of 0.63. The company has a 50-day moving average price of $75.06 and a two-hundred day moving average price of $67.74. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $96.37.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $211.37 million for the quarter, compared to analysts' expectations of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business's revenue for the quarter was up 53.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 EPS. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Zacks Research raised shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. HC Wainwright reissued a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Piper Sandler reissued an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $84.75.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 50,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total value of $4,303,500.00. Following the completion of the sale, the chief financial officer directly owned 180,863 shares of the company's stock, valued at approximately $15,566,878.41. This represents a 21.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Nikhil Lalwani sold 56,960 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total transaction of $4,894,572.80. Following the sale, the chief executive officer directly owned 411,219 shares of the company's stock, valued at approximately $35,336,048.67. This trade represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 405,538 shares of company stock worth $35,690,131. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.